Iberoamerican Pharmacometrics Network Congress 2018 Report: Fostering Modeling and Simulation Approaches for Drug Development and Regulatory and Clinical Applications in Latin America

@article{Ibarra2019IberoamericanPN,
  title={Iberoamerican Pharmacometrics Network Congress 2018 Report: Fostering Modeling and Simulation Approaches for Drug Development and Regulatory and Clinical Applications in Latin America},
  author={Manuel Ibarra and Teresa Dalla Costa and Paula Schaiquevich and Rodrigo Cristofoletti and Ignacio Hern{\'a}ndez Gonz{\'a}lez and Nicte Selene Fajardo-Robledo and Marcela Arag{\'o}n Novoa and Maris{\'i}n Pecchio and Ignacio Cort{\'i}nez and I{\~n}aki F. Troc{\'o}niz and Elba M. Romero-Tejeda},
  journal={CPT: Pharmacometrics \& Systems Pharmacology},
  year={2019},
  volume={8},
  pages={197 - 200}
}
This report provides a brief description of the 2018 RedIF Congress that took place in Guadalajara (Mexico), on November 7-9. The meeting aimed to foster modeling & simulation approaches for drug development, regulatory sciences and clinical application in Latin America. Organizations that cosponsored the meeting were: University of Guadalajara, International Society of Pharmacometrics (ISoP), International Pharmaceutical Federation (FIP), Clinic of Chronic Diseases and Special Procedures… 
3 Citations
CPT: Pharmacometrics & Systems Pharmacology 2.0
  • F. Mentré
  • Medicine
    CPT: pharmacometrics & systems pharmacology
  • 2019
TLDR
The new Editorial Team of PSP is presented and the primary goals are to increase articles from outside the United States and Europe and to encourage submissions from and be more visible at the Word Conference on Pharmacometrics.
What “Impact” Do NLME Publications Have Outside Our Community?
TLDR
This work evaluated articles that have used NLME modeling, were published in journals that attract a broader audience, and discussed the standard of presentation of these to stimulate target audience‐specific improvements for increased impact in the future.

References

SHOWING 1-8 OF 8 REFERENCES
Pharmacometrics: Opportunity for Reducing Disease Burden in the Developing World: The Case of Africa
TLDR
The case for pharmacometricians to redirect their expertise to focus on the disease burden affecting the developing world is outlined.
Model‐Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development
TLDR
The role model‐based drug development approaches can and do play in accelerating and optimizing compound development strategies through a series of illustrative examples are discussed.
Model‐Informed Drug Discovery and Development: Current Industry Good Practice and Regulatory Expectations and Future Perspectives
TLDR
A survey targeted to clinical pharmacology and pharmacometric colleagues across industry, the US Food and Drug Administration, and the European Medicines Agency was conducted to understand current and future roles of MID3.
The intellectual health of clinical drug evaluation
  • L. Sheiner
  • Medicine, Psychology
    Clinical pharmacology and therapeutics
  • 1991
TLDR
It is necessary to select patients suitable for vaginal or laparoscopic mesh placement on the basis of prior history and once they provide informed consent for surgery, the likelihood of adverse events and their prognosis is low.
Model-Based Residual Post-Processing for Residual Model Identification
TLDR
This study investigated if model-based post-processing of common diagnostics can be used as a diagnostic tool to quantitatively identify model misspecifications and rectifying actions and found agreement in improvement in goodness-of-fit between implementing these extended RUV models on the original model.
What “Impact” Do NLME Publications Have Outside Our Community?
TLDR
This work evaluated articles that have used NLME modeling, were published in journals that attract a broader audience, and discussed the standard of presentation of these to stimulate target audience‐specific improvements for increased impact in the future.